Imperial increases investment in TopiVert
Imperial Innovations has injected a further £4.5m into existing portfolio company TopiVert, a UK-based developer of treatments for inflammatory eye and gut diseases.
The capital injection brings the total amount committed to TopiVert by Imperial to £8.5m in equity.
The funding round also saw previous investor SV Life Sciences contribute fresh capital, as well as new backers NeoMed Management and Johnson & Johnson Development Corporation.
Previous funding
In December 2011, Imperial and SV Life Sciences backed TopiVert with an £8m early-stage investment.
Company
Headquartered in London, TopiVert is in pre-revenue stages and is currently developing its narrow spectrum kinase inhibitor (NSKI) technology.
The company is aiming to identify new NSKIs for the purpose of creating treatments for inflammatory diseases in the eye and gut, such as uveitis and inflammatory bowel disease (IBS).
People
Maina Bhaman is a director of healthcare investments at Imperial, and also sits on TopiVert's board of directors.
More on UK / Ireland
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater